<DOC>
	<DOCNO>NCT00001079</DOCNO>
	<brief_summary>To test hypothesis predominant accrual fat rather lean body mass ( LBM ) occur treatment HIV-associated wasting megestrol acetate may improve treatment megestrol acetate testosterone enanthate combination . Body waste increasingly frequent AIDS-defining condition individual infect HIV . Increasing caloric intake fails consistently restore lean tissue patient HIV associate weight loss . Megestrol acetate show stimulate appetite weight gain subject cancer HIV associate weight loss . However , weight gain treatment megestrol acetate predominantly exclusively fat . An important factor preferential increase body fat see study may due hypogonadism occur result treatment megestrol acetate , progestational agent . Hypogonadism associated increase body fat decrease LBM . Concomitant testosterone replacement substantially increase amount LBM accrue megestrol acetate therapy . This study determine whether anabolic potential realize caloric intake increase absence concomitant hypogonadism .</brief_summary>
	<brief_title>A Study Megestrol Acetate Alone Combination With Testosterone Enanthate Drug Treatment HIV-Associated Weight Loss</brief_title>
	<detailed_description>Body waste increasingly frequent AIDS-defining condition individual infect HIV . Increasing caloric intake fails consistently restore lean tissue patient HIV associate weight loss . Megestrol acetate show stimulate appetite weight gain subject cancer HIV associate weight loss . However , weight gain treatment megestrol acetate predominantly exclusively fat . An important factor preferential increase body fat see study may due hypogonadism occur result treatment megestrol acetate , progestational agent . Hypogonadism associated increase body fat decrease LBM . Concomitant testosterone replacement substantially increase amount LBM accrue megestrol acetate therapy . This study determine whether anabolic potential realize caloric intake increase absence concomitant hypogonadism . This 24 week study consist 12 week double blind , randomize comparison Phase II trial megestrol acetate testosterone enanthate combination versus megestrol acetate plus testosterone enanthate placebo HIV associate waste 12 week open label follow combination therapy .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Wasting Syndrome</mesh_term>
	<mesh_term>HIV Wasting Syndrome</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Megestrol Acetate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Stable antiretroviral therapy provide patient &gt; =30 day prior study entry . AS PER AMENDMENT 9/26/97 : Optimized antiretroviral therapy determine primary care provider least 30 day since initiation therapy . Standard maintenance prophylaxis therapy opportunistic infection permit provided patient stable dosage regimen 2 week prior screen . GCSF . Erythropoietin . Any symptomatic therapy ( e.g. , analgesic , antihistamine , antiemetic , antidiarrheal agent , etc. ) . Replacement level thyroid drug ( drug dose 30 day preentry ) . Maintenance therapy permit chronic opportunistic infection , patient must stable regimen 14 day preentry . AS PER AMENDMENT 9/26/97 : Oral nutritional supplement , dronabinol , cyproheptadine , pentoxifylline . Patients must : Documented HIV1 infection . Documented weight loss &gt; 10 % preillness weight Body Mass Index &lt; 18.5 kg/m2 . AS PER AMENDMENT 9/26/97 : Documented weight loss &gt; = 5 % preillness weight Body Mass Index &lt; 20 kg/m2 . Life expectancy least 6 month . NOTE : This protocol meet federal requirement govern prisoner participation clinical trial . Prior Medication : Allowed : Stable ( change drug dosage ) antiretroviral therapy antiretroviral medication &gt; = 30 day prior study entry . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Diabetes mellitus . Diarrhea define 4 liquid watery stool per day use antidiarrheal medication . Tube feed . AS PER AMENDMENT 9/26/97 : Total partial parenteral nutrition deliver centrally peripherally . Impaired oral intake due mucositis cause . Grade 2 great intractable nausea vomit despite medication . Cardiomyopathy congestive heart failure . Persistent palpable dominant breast mass study entry work male female . Female patient : Pap smear cervical biopsy demonstrate high grade squamous intraepithelial lesion cervical intraepithelial lesion 2 bad . Concurrent Medication : Excluded : Systemic chemotherapy Bcell lymphoma malignancy Kaposi 's sarcoma . ( Patients Kaposi 's sarcoma receive systemic chemotherapy exclude . ) Total peripheral parenteral nutrition ( oral supplement exclude ) . Anticoagulant therapy . Any drug design affect appetite weight gain . AS PER AMENDMENT 9/26/97 : Initiation new therapy design promote weight gain . Any change antiretroviral change dosage antiretroviral/s start 30 day preentry . AS PER AMENDMENT 9/26/97 : Initiation antiretroviral therapy within 12 week protocol therapy patient previously receive antiretroviral therapy . Anabolic hormone . Systemic glucocorticoid . Cytokine inhibitor . Oral contraceptive . Cytokines . Ketoconazole . Any medication might interfere objective study . AS PER AMENDMENT 9/26/97 : DHEA . Patients follow prior condition exclude : Acute systemic opportunistic infection within 30 day prior entry . Weight gain &gt; = 3 % document self report clinical record precede 4 week . AS PER AMENDMENT 9/26/97 : Enrollment patient defer weight stabilizes . History hypersensitivity reaction megestrol acetate testosterone enanthate . History cardiomyopathy congestive heart failure . Female patient : History invasive cervical cancer . AS PER AMENDMENT 9/26/97 : History thromboemboli . Prior Medication : Excluded : No testosterone treatment within previous 8 week . Excluded within 30 day prior entry : Ketoconazole . Initiation change antiretroviral therapy . Interleukins . Interferon , anabolic , hormonal experimental therapy design improve appetite weight gain ( e.g. , thalidomide , dronabinol , megestrol acetate , cyproheptadine , anabolic steroid , systemic glucocorticoid , pentoxifylline , growth hormone ) . AS PER AMENDMENT 9/26/97 : Dehydroepiandrosterone ( DHEA ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Placebos</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>HIV Wasting Syndrome</keyword>
	<keyword>Megestrol Acetate</keyword>
	<keyword>dihydrotestosterone heptanoate</keyword>
</DOC>